WallStreetZenWallStreetZen

NASDAQ: HIND
Vyome Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for HIND

Based on 1 analyst offering 12 month price targets for Vyome Holdings Inc

Min Forecast
$15.00+336.05%
Avg Forecast
$15.00+336.05%
Max Forecast
$15.00+336.05%

Should I buy or sell HIND stock?

Based on 1 analyst offering ratings for Vyome Holdings Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HIND stock forecasts and price targets.

HIND stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-02

1 of 1

Forecast return on equity

Is HIND forecast to generate an efficient return?

Company
-316.35%
Industry
20.76%
Market
342.1%
HIND's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HIND forecast to generate an efficient return on assets?

Company
-113.59%
Industry
11.72%
HIND is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HIND earnings per share forecast

What is HIND's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.84
Avg 2 year Forecast
-$1.42

HIND revenue forecast

What is HIND's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
HIND's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HIND revenue growth forecast

How is HIND forecast to perform vs Medical Devices companies and vs the US market?

Company
-100%
Industry
30.35%
Market
1,472.44%
HIND's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HIND's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HIND vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
HIND$3.44$15.00+336.05%Strong Buy
IRIX$1.14N/AN/A
COCH$0.66N/AN/A
VVOS$2.03$6.25+207.88%Buy
NSYS$7.43N/AN/A
View Top Medical Device Stocks

Vyome Holdings Stock Forecast FAQ

Is Vyome Holdings Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: HIND) stock is to Strong Buy HIND stock.

Out of 1 analyst, 1 (100%) are recommending HIND as a Strong Buy, 0 (0%) are recommending HIND as a Buy, 0 (0%) are recommending HIND as a Hold, 0 (0%) are recommending HIND as a Sell, and 0 (0%) are recommending HIND as a Strong Sell.

If you're new to stock investing, here's how to buy Vyome Holdings stock.

What is HIND's earnings growth forecast for 2026-2027?

(NASDAQ: HIND) Vyome Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 39.29%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,192.7%.

Vyome Holdings's earnings in 2025 is -$11,350,811.On average, 3 Wall Street analysts forecast HIND's earnings for 2026 to be -$4,721,055, with the lowest HIND earnings forecast at -$4,535,915, and the highest HIND earnings forecast at -$4,859,909.

In 2027, HIND is forecast to generate -$8,002,764 in earnings, with the lowest earnings forecast at -$7,688,930 and the highest earnings forecast at -$8,238,139.

What is HIND's revenue growth forecast for 2026-2027?

(NASDAQ: HIND) Vyome Holdings's forecast annual revenue growth rate of -100% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 30.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,472.44%.

Vyome Holdings's revenue in 2025 is $4,194,627.On average, 3 Wall Street analysts forecast HIND's revenue for 2026 to be $0, with the lowest HIND revenue forecast at $0, and the highest HIND revenue forecast at $0.

In 2027, HIND is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is HIND's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: HIND) forecast ROA is -113.59%, which is lower than the forecast US Medical Devices industry average of 11.72%.

What is HIND's Price Target?

According to 1 Wall Street analyst that have issued a 1 year HIND price target, the average HIND price target is $15.00, with the highest HIND stock price forecast at $15.00 and the lowest HIND stock price forecast at $15.00.

The Wall Street analyst predicted that Vyome Holdings's share price could reach $15.00 by Oct 2, 2026. The average Vyome Holdings stock price prediction forecasts a potential upside of 336.05% from the current HIND share price of $3.44.

What is HIND's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: HIND) Vyome Holdings's current Earnings Per Share (EPS) is -$125.12. On average, analysts forecast that HIND's EPS will be -$0.84 for 2026, with the lowest EPS forecast at -$0.80, and the highest EPS forecast at -$0.86. In 2027, HIND's EPS is forecast to hit -$1.42 (min: -$1.36, max: -$1.46).

What is HIND's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: HIND) forecast ROE is -316.35%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.